Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis with meta-regression of observational studies

International Journal of Dermatology

Volumn 54, Issue 1, 2015, Pages 108-115

  Barron, Stacy J ^a   Del Vecchio, Michael T ^b   Aronoff, Stephen C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ARTICLE; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; SCORING SYSTEM; SCORTEN SCALE; STANDARDIZED MORTALITY RATE; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; STEVENS-JOHNSON SYNDROME;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; OBSERVATIONAL STUDY AS TOPIC; STEVENS-JOHNSON SYNDROME;

EID: 84919841976     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12423     Document Type: Article

References (37)

1. Borchers AT, Lee JL, Naguwa SM, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598-605.
2. Mittmann N, Chan B, Knowles S, et al. IVIG for the treatment of toxic epidermal necrolysis. Skin Therapy Lett 2007; 12: 7-9.
3. Trent JT, Ma F, Kerbel F, et al. Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis. Expert Rev Dermatol 2007; 2: 299-303.
4. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96.
5. Zaoutis LB, Chang VW, eds. Comprehensive Pediatric Hospital Medicine. Philadelphia, PA: Mosby, 2007; 1016-1019.
6. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.
7. Roujeau JC, Bastuji-Garin S. Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. Ther Adv Drug Safety 2011; 2: 87-94.
8. Huang Y-C, Li Y-C, Chen T-J. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 2012; 167: 424-432.
9. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies. JAMA 2000; 283: 2008-2012.
10. Imahara SD, Holmes JH, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standard treatment protocol. J Burn Care Res 2004; 27: 270-275.
11. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153.
12. Liddell FD. Simple exact analysis of the standardized mortality ratio. J Epidemiol Community Health 1984; 38: 85-88.
13. Ury HK, Wiggins A. Another shortcut method for calculating the confidence interval of a Poisson variable (of a standardized mortality ratio). Am J Epidemiol 1985; 122: 197-198.
14. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-129.
15. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-729.
17. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
18. Lissia M, Figus A, Rubino C. Intravenous immunoglobulin and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 2005; 58: 504-510.
19. Yip LW, Thong BY, Tan AW, et al. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye 2005; 19: 846-853.
20. Schneck J, Fagot J-P, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40.
21. Gerdts B, Vloemans AF, Kreis RW. Toxic epidermal necrolysis: 15 years' experience in a Dutch burns center. J Eur Acad Dermatol Venereol 2007; 21: 781-788.
22. Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25: 246-255.
23. Koh MJ-A, Tay Y-K. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol 2010; 62: 54-60.
24. Morici M. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol 2000; 27: 2494-2497.
25. Campione E, Marulli G, Carrozzo AM, et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003; 83: 430-432.
26. Chen J, Wang B, Zeng Y, et al. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol 2010; 20: 743-747.
27. Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 2005; 85: 497-502.
28. Rajaratnam R, Mann C, Balasubramaniam P, et al. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary center. Clin Exp Dermatol 2010; 35: 853-862.
29. Spornraft-Ragaller P, Theilen H, Gottschlich GS, et al. Treatment of toxic epidermal necrolysis. Experience with nine patients with consideration of intravenous immunoglobulin. Hautarzt 2006; 57: 185-194.
30. Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007; 33: 452-459.
31. Tan S-K, Tay Y-K. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol 2012; 92: 62-66.
32. Teo L, Tay YK, Liu TT, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options. Singapore Med J 2009; 50: 29-33.
33. Trent JT, Kirsner RS, Romanelli P, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 2003; 139: 39-43.
34. Yang Y, Xu J, Li F, et al. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol 2009; 48: 1122-1129.
35. Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol 2005; 30: 600-602.
36. Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004; 25: 81-88.
37. Bachot N, Revuz J, Roujeau J-C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective non-comparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-36.